• If you are wondering whether Arrowhead Pharmaceuticals' current share price lines up with its fundamentals, this article walks through the key valuation angles that matter to you.
• The stock last closed at US$74.81, with returns of 1.2% over 7 days, 18.9% over 30 days, 10.4% year to date, 418.8% over 1 year and 80.8% over 3 years, compared with 12.7% over 5 years.
• Recent market focus around Arrowhead Pharmaceuticals has centred on its position in the biopharmaceutical space and ongoing interest in RNA based therapies. This context helps frame why shorter term moves sit alongside a very strong 1 year return figure.
• Arrowhead Pharmaceuticals currently has a valuation score of 2 out of 6. The next sections break down what different valuation methods say about that score, and then finish with a broader way to think about what valuation really means for your decision making.

Arrowhead Pharmaceuticals scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Arrowhead Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of a company’s future cash flows and discounts them back to today using a required return, giving an estimate of what the business might be worth right now.

For Arrowhead Pharmaceuticals, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $79.1 million. Analyst inputs and extrapolated estimates point to free cash flow of $354.85 million by 2030, with interim years including both cash outflows and inflows as the business investment and funding profile shifts over time.

Simply Wall St aggregates these projections, discounts each year’s cash flows to today, and arrives at an estimated intrinsic value of US$145.37 per share. Against the recent share price of US$74.81, this suggests the stock is trading at about a 48.5% discount to that DCF estimate, which indicates Arrowhead Pharmaceuticals may be undervalued on this cash flow based view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Arrowhead Pharmaceuticals is undervalued by 48.5%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Arrowhead Pharmaceuticals Price vs Earnings

For a profitable company, the P/E ratio is a useful shorthand for how much investors are paying for each dollar of earnings. This metric is often considered an anchor for long term returns. Higher growth expectations and lower perceived risk usually justify a higher P/E, while slower growth or higher risk typically align with a lower, more conservative range.

Arrowhead Pharmaceuticals currently trades on a P/E of 51.79x. That sits above the Biotechs industry average of 17.28x and the peer group average of 26.77x, so the market is assigning a richer earnings multiple than these broad benchmarks suggest. Simply Wall St also calculates a “Fair Ratio” of 16.59x for Arrowhead Pharmaceuticals. This reflects the P/E that would typically be expected given factors such as its earnings profile, industry, profit margins, market cap and assessed risks.

This Fair Ratio is more tailored than a simple industry or peer comparison because it adjusts for company specific features instead of assuming all biotechs should trade on the same multiple. Comparing the current P/E of 51.79x with the Fair Ratio of 16.59x indicates the shares are trading above that customised range.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Arrowhead Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives bring your view of Arrowhead Pharmaceuticals together into a single story that links your expectations for future revenue, earnings and margins to a fair value, then compares that to today’s price to help you decide whether the stock looks attractive or expensive.

On Simply Wall St’s Community page, Narratives are an accessible tool used by millions of investors. You can see different fair values update automatically as new earnings, news or clinical data arrive, instead of trying to manually adjust every assumption yourself.

For example, some investors currently align with a more cautious Arrowhead Pharmaceuticals Narrative that points to a fair value around US$42.57. Others back a more optimistic Narrative closer to US$110.00. By seeing these side by side you can quickly judge which story feels closer to your own expectations and how that compares with the current share price.

For Arrowhead Pharmaceuticals, here are previews of two leading Arrowhead Pharmaceuticals Narratives:

Fair value: US$110.00

Gap to this fair value versus the last close of US$74.81: about 32.0% below the bullish fair value

Revenue growth assumption: 8.28% annual decline

• Leans on rapid clinical progress in obesity and cardiometabolic programs, together with global partnerships, as support for higher long term earnings potential than current pricing reflects.
• Assumes revenue of US$841.7m and earnings of US$124.2m by 2029, with the market paying a P/E of 159.3x on those earnings to reach a fair value of US$110.00.
• Flags meaningful risks around trial costs, concentrated pipeline exposure, competition from other RNA and gene based therapies, and drug pricing reforms that could pressure margins.

Fair value: US$42.57

Gap to this fair value versus the last close of US$74.81: about 75.7% above the bearish fair value

Revenue growth assumption: 32.78% annual decline

• Focuses on pressure from stricter healthcare reimbursement, faster generic and biosimilar entry, and emerging gene editing approaches as headwinds for pricing power and future earnings.
• Assumes revenue of US$331.3m and earnings of US$49.1m by 2029, with a P/E of 156.1x on those earnings to justify a fair value of US$42.57.
• Accepts that a broad late stage pipeline and big pharma partnerships could still support growth, but argues current pricing already builds in generous success across multiple programs.

These two Narratives frame a reasonable range of outcomes around the same company, using different assumptions about revenue trends, margins and what multiple the market might be willing to pay in a few years time. The key step for you is to decide which story feels closer to your own expectations, or whether your view sits somewhere in between.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Arrowhead Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Arrowhead Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.